- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.02. | Pasithea Therapeutics Corp. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.01. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.01. | Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | 154 | GlobeNewswire (Europe) | MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral... ► Artikel lesen | |
| 15.12.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright | 2 | Investing.com | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.12.25 | Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
| 28.11.25 | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | 1 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up | 4 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | Pasithea Therapeutics Corp. - S-1/A, General form for registration of securities | 14 | SEC Filings | ||
| 25.11.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | ALS Association awards $1 million to study Pasithea's PAS-004 in ALS | 2 | Investing.com | ||
| 24.11.25 | Pasithea reports positive safety data from PAS-004 cancer trial | 7 | Investing.com | ||
| 21.11.25 | Pasithea reports positive PK data for PAS-004 tablet formulation | 1 | Investing.com | ||
| 21.11.25 | Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | 285 | GlobeNewswire (Europe) | -- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with... ► Artikel lesen | |
| 20.11.25 | Pasithea meldet positive Zwischendaten für MEK-Inhibitor in Krebsstudie | 5 | Investing.com Deutsch | ||
| 20.11.25 | Pasithea reports positive interim data for MEK inhibitor in cancer trial | 1 | Investing.com | ||
| 20.11.25 | Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | 219 | GlobeNewswire (Europe) | -- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge... ► Artikel lesen | |
| 18.11.25 | Pasithea Therapeutics Corp. - S-1, General form for registration of securities | - | SEC Filings | ||
| 13.11.25 | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,899 | +9,30 % | Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy | ||
| ABIVAX | 100,80 | -4,91 % | Abivax-Aktie: Die Entscheidung naht | Während sich bei Abivax derzeit alles um eine potenzielle und möglicherweise sehr lukrative Übernahme zu drehen scheint, ist klar: Auch als eigenständiges Biotechunternehmen sind die Perspektiven für... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,510 | -2,08 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| GENPREX | 1,920 | 0,00 % | Genprex collaborators to present lung cancer data at AACR meeting | ||
| REZOLUTE | 2,160 | +0,93 % | Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update | REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all... ► Artikel lesen | |
| SPRUCE BIOSCIENCES | 59,00 | +1,94 % | SPRUCE BIOSCIENCES, INC. - 8-K, Current Report | ||
| UNICYCIVE THERAPEUTICS | 6,770 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission | DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE... ► Artikel lesen | |
| DAMORA THERAPEUTICS | 23,075 | 0,00 % | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| FIBROBIOLOGICS | 0,236 | +9,26 % | FibroBiologics, Inc.: FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology | HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARCELLX | 114,61 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen |
PASITHEA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,39 % bei einem Aktienkurs von 0,781 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.